Trxade Group, Inc. (NASDAQ: MEDS) Telehealth App I
Post# of 174
(Total Views: 233)
Posted On: 07/13/2020 3:20:05 PM
Trxade Group, Inc. (NASDAQ: MEDS) Telehealth App Incorporates New Educational Resources for Patients
- Pharmaceutical and health care services company Trxade Group has added new tools to its Bonum Health telemedicine platform that will help patients better inform themselves about their medical needs and their provider’s prescription recommendations
- Trxade Group operates a B2B pharmaceutical network that supports independent, neighborhood-based healthcare businesses with up-to-the-minute information on drug pricing
- The company also assists patients on a B2C basis through its subsidiaries that include Bonum Health’s telemedicine platform and Delivmeds’ pharmaceutical delivery service
- Trxade Group’s development of remote-access medical care during the past two years has proven timely in the face of restrictions on gatherings imposed during the novel coronavirus pandemic
- The company has been increasing its profile among investors with uplisting to the Nasdaq exchange and entry to the annual Russell’s Microcap Index
Growing health services provider Trxade Group (NASDAQ: MEDS) recently announced the expansion of its patient empowerment telehealth platform Bonum Health, which has added access to educational resources that can help better understand and direct their care management.
Trxade Group’s wholly owned mobile telehealth application will now link to the Merck Manual, a standard reference guide for physicians since 1899, according to the announcement. The company’s intent in further developing the Bonum Health app is to “encourage, enable, and empower patients” with information pertinent to their medical needs and provider’s drug recommendations.
Trxade Group has been undergoing significant portfolio development during recent months. The company’s mission is to help sustain independent, locally owned community pharmacies, and two years ago it boosted its own capacity to reach consumers directly when it acquired accredited Internet pharmaceutical Community Specialty Pharmacy, LLC (http://nnw.fm/8vwSD) and launched its consumer-based medication delivery app Delivmeds.com.
Trxade Group has since added its Bonum Health Hub telehealth service as a means for patients and providers to consult using mobile smart tech without a need for in-office visits. The secure, privacy-enabled technology has proven particularly timely during a year when a novel coronavirus reached pandemic-level global transmission and spurred health and government leaders to enact varied restrictions against group gatherings (http://nnw.fm/s3oUQ).
Trxade Group has this year seen its operation uplisted to the Nasdaq exchange as it has gathered funding, and last month it gained inclusion on this year’s Russell’s Microcap Index.
“This marks an exciting capital markets milestone in the growth and trajectory of our company as we continue to execute upon our growth strategy and raise awareness about the Company throughout the investment community,” Trxade Chairman and CEO Suren Ajjarapu stated in a news release at the time (http://nnw.fm/poK7m).
Trxade Group’s eBay-type B2B business model significantly lowers prescription drug costs, in part due to its emphasis on transparency. At the same time, the company’s revenues grew 94 percent during 2019 as a result of fee income for medications listed on the company’s web-based market platform (http://nnw.fm/bFr3J) and 11,400 independent pharmacies became new subscribers to the company’s platform for analyzing drug pricing on an up-to-the-minute basis.
For more information, visit the company’s website at www.TrxadeGroup.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Pharmaceutical and health care services company Trxade Group has added new tools to its Bonum Health telemedicine platform that will help patients better inform themselves about their medical needs and their provider’s prescription recommendations
- Trxade Group operates a B2B pharmaceutical network that supports independent, neighborhood-based healthcare businesses with up-to-the-minute information on drug pricing
- The company also assists patients on a B2C basis through its subsidiaries that include Bonum Health’s telemedicine platform and Delivmeds’ pharmaceutical delivery service
- Trxade Group’s development of remote-access medical care during the past two years has proven timely in the face of restrictions on gatherings imposed during the novel coronavirus pandemic
- The company has been increasing its profile among investors with uplisting to the Nasdaq exchange and entry to the annual Russell’s Microcap Index
Growing health services provider Trxade Group (NASDAQ: MEDS) recently announced the expansion of its patient empowerment telehealth platform Bonum Health, which has added access to educational resources that can help better understand and direct their care management.
Trxade Group’s wholly owned mobile telehealth application will now link to the Merck Manual, a standard reference guide for physicians since 1899, according to the announcement. The company’s intent in further developing the Bonum Health app is to “encourage, enable, and empower patients” with information pertinent to their medical needs and provider’s drug recommendations.
Trxade Group has been undergoing significant portfolio development during recent months. The company’s mission is to help sustain independent, locally owned community pharmacies, and two years ago it boosted its own capacity to reach consumers directly when it acquired accredited Internet pharmaceutical Community Specialty Pharmacy, LLC (http://nnw.fm/8vwSD) and launched its consumer-based medication delivery app Delivmeds.com.
Trxade Group has since added its Bonum Health Hub telehealth service as a means for patients and providers to consult using mobile smart tech without a need for in-office visits. The secure, privacy-enabled technology has proven particularly timely during a year when a novel coronavirus reached pandemic-level global transmission and spurred health and government leaders to enact varied restrictions against group gatherings (http://nnw.fm/s3oUQ).
Trxade Group has this year seen its operation uplisted to the Nasdaq exchange as it has gathered funding, and last month it gained inclusion on this year’s Russell’s Microcap Index.
“This marks an exciting capital markets milestone in the growth and trajectory of our company as we continue to execute upon our growth strategy and raise awareness about the Company throughout the investment community,” Trxade Chairman and CEO Suren Ajjarapu stated in a news release at the time (http://nnw.fm/poK7m).
Trxade Group’s eBay-type B2B business model significantly lowers prescription drug costs, in part due to its emphasis on transparency. At the same time, the company’s revenues grew 94 percent during 2019 as a result of fee income for medications listed on the company’s web-based market platform (http://nnw.fm/bFr3J) and 11,400 independent pharmacies became new subscribers to the company’s platform for analyzing drug pricing on an up-to-the-minute basis.
For more information, visit the company’s website at www.TrxadeGroup.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)